Literature DB >> 23182714

Role of complement in a murine model of peanut-induced anaphylaxis.

Toshihisa Kodama1, Hideharu Sekine, Minoru Takahashi, Daisuke Iwaki, Takeshi Machida, Kazuko Kanno, Yumi Ishida, Yuichi Endo, Teizo Fujita.   

Abstract

Peanut allergy is severe and persisting from childhood to adulthood. However, there is no effective prophylaxis or treatment for peanut allergy. Little is known to about the molecular process in the pathogenesis of peanuts allergy, especially in innate immunity. Thus we investigated the role of complement activation in murine peanut anaphylaxis. Complement component C3 deposition on peanut extract (PE) was evaluated using sera from wild-type (WT), mannose-binding lectin associated serine protease (MASP)-1/3 deficient, MASP-2 deficient, and C4 deficient mice. Sera from interferon regulatory factor-4 (IRF-4) deficient mice, which lack serum immunoglobulin, were also used. In anaphylaxis study, mice were pretreated with propranolol and a long-acting form of IL-4, and injected with PE. Mice were then assessed for plasma C3a levels and hypothermia shock by ELISA and rectal temperature measurement, respectively. C3 deposition on PE was abolished in immunoglobulin- and C4-deficient sera. No difference in C3 deposition levels were observed among WT, MASP-1/3 deficient and MASP-2 deficient sera. IgM, IgG2b, IgG3, C1q, and ficolin-A deposits were detected on PE. In anaphylaxis study, MASP-1/3 deficient mice showed elevation of plasma C3a levels similar to WT mice. However, they were significantly reduced in C4- and MASP-2-deficient mice compared to WT mice. Consistently, PE-induced anaphylactic shock was prevented in C4 deficient mice and partially in MASP-2 deficient mice. In conclusion, PE activates complement via both the lectin and classical pathways in vivo, and the complement activation contributes to hypothermia shock in mice.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182714     DOI: 10.1016/j.imbio.2012.10.003

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  8 in total

1.  Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.

Authors:  Z Shao; T Nishimura; L L K Leung; J Morser
Journal:  J Thromb Haemost       Date:  2015-05-10       Impact factor: 5.824

Review 2.  Allergic reaction to peanuts: can we predict reaction severity in the wild?

Authors:  Aisling Flinn; Jonathan O'B Hourihane
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

Review 3.  The pathophysiology of anaphylaxis.

Authors:  Laurent L Reber; Joseph D Hernandez; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

Review 4.  Human IgE-independent systemic anaphylaxis.

Authors:  Fred D Finkelman; Marat V Khodoun; Richard Strait
Journal:  J Allergy Clin Immunol       Date:  2016-04-26       Impact factor: 10.793

Review 5.  Pathophysiological, Cellular, and Molecular Events of the Vascular System in Anaphylaxis.

Authors:  Emilio Nuñez-Borque; Sergio Fernandez-Bravo; Alma Yuste-Montalvo; Vanesa Esteban
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

6.  Toll-like receptor 2 activators modulate oral tolerance in mice.

Authors:  M C Tunis; B Dawod; K R Carson; L L Veinotte; J S Marshall
Journal:  Clin Exp Allergy       Date:  2015-11       Impact factor: 5.018

7.  Proteomic and Biological Analysis of an In Vitro Human Endothelial System in Response to Drug Anaphylaxis.

Authors:  Alma Yuste-Montalvo; Sergio Fernandez-Bravo; Tamara Oliva; Carlos Pastor-Vargas; Diana Betancor; María José Goikoetxea; José Julio Laguna; Juan Antonio López; Gloria Alvarez-Llamas; Javier Cuesta-Herranz; Marta Martin-Lorenzo; Vanesa Esteban
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 8.  Complement, a target for therapy in inflammatory and degenerative diseases.

Authors:  B Paul Morgan; Claire L Harris
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 112.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.